Alta Pharmaceutical Research Center — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$27,017	2
2023	Research	$27,507	6
2021	Research	$63,152	2
2020	Research	$31,478	1
2019	Research	$3,000	2

Breakdown

Who paid Research payments · program years 2019–2024

Novartis Pharmaceuticals Corporation $135,021 10 payments
AstraZeneca UK Limited $14,133 1 payment
Relypsa, Inc. $3,000 2 payments

Studies the money was for Research payments · program years 2019–2024

An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $82,983 3 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $37,585 3 payments
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $14,453 4 payments
A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $14,133 1 payment
Amber $3,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.